KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Change in Account Payables (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Change in Account Payables data on record, last reported at $3.3 million in Q4 2025.

  • For Q4 2025, Change in Account Payables rose 802.73% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $3.9 million, up 201.29%, while the annual FY2025 figure was $3.9 million, 201.29% up from the prior year.
  • Change in Account Payables reached $3.3 million in Q4 2025 per RIGL's latest filing, up from -$3.4 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $4.8 million in Q4 2022 and bottomed at -$3.4 million in Q3 2025.
  • Average Change in Account Payables over 5 years is $175600.0, with a median of $600500.0 recorded in 2022.
  • Peak YoY movement for Change in Account Payables: crashed 383.68% in 2021, then soared 802.73% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at $697000.0 in 2021, then skyrocketed by 586.8% to $4.8 million in 2022, then plummeted by 117.9% to -$857000.0 in 2023, then soared by 44.46% to -$476000.0 in 2024, then skyrocketed by 802.73% to $3.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $3.3 million in Q4 2025, -$3.4 million in Q3 2025, and $3.3 million in Q2 2025.